Ordering
Available Variants5 mg
CHA.74368-5mg
Price
€396.00
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.74368-5mg | €396.00 |
≥98% (HPLC), powder, caffeine inhibitor
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C12H12N4O3 |
|---|---|
| CAS Number | 80288-49-9 |
| Molecular Weight | 260.25 |
| UNSPSC Code | 41106305 |
| PubChem Substance ID | 24278813 |
| NACRES | NA.77 |
| MDL number | MFCD00153799 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
| ppe | Eyeshields, Gloves, type N95 (US) |
Technical Overview & Applications Use-case context
Furafylline, with a CAS number of 80288-49-9, is a potent and selective inhibitor of cytochrome P450 1A2, an enzyme involved in the metabolism of various xenobiotics. As an inhibitor of this enzyme, furafylline has been investigated for its potential to modulate the pharmacokinetics and pharmacodynamics of co-administered drugs that are substrates of CYP1A2. The compound has been shown to exhibit high affinity and specificity for CYP1A2, with minimal activity towards other cytochrome P450 isoforms. Furafyllines inhibitory effects on CYP1A2 have been characterized in vitro and in vivo, and its potential applications include the optimization of drug therapies and the reduction of adverse drug interactions. Further research is needed to fully elucidate the clinical utility and safety profile of furafylline as a CYP1A2 inhibitor.
